Literature DB >> 34172578

Stat3 loss in mesenchymal progenitors causes Job syndrome-like skeletal defects by reducing Wnt/β-catenin signaling.

Prem Swaroop Yadav1, Shuhao Feng1, Qian Cong1, Hanjun Kim1, Yuchen Liu1, Yingzi Yang2,3.   

Abstract

Job syndrome is a rare genetic disorder caused by STAT3 mutations and primarily characterized by immune dysfunction along with comorbid skeleton developmental abnormalities including osteopenia, recurrent fracture of long bones, and scoliosis. So far, there is no definitive cure for the skeletal defects in Job syndrome, and treatments are limited to management of clinical symptoms only. Here, we have investigated the molecular mechanism whereby Stat3 regulates skeletal development and osteoblast differentiation. We showed that removing Stat3 function in the developing limb mesenchyme or osteoprogenitor cells in mice resulted in shortened and bow limbs with multiple fractures in long bones that resembled the skeleton symptoms in the Job Syndrome. However, Stat3 loss did not alter chondrocyte differentiation and hypertrophy in embryonic development, while osteoblast differentiation was severely reduced. Genome-wide transcriptome analyses as well as biochemical and histological studies showed that Stat3 loss resulted in down-regulation of Wnt/β-catenin signaling. Restoration of Wnt/β-catenin signaling by injecting BIO, a small molecule inhibitor of GSK3, or crossing with a Lrp5 gain of function (GOF) allele, rescued the bone reduction phenotypes due to Stat3 loss to a great extent. These studies uncover the essential functions of Stat3 in maintaining Wnt/β-catenin signaling in early mesenchymal or osteoprogenitor cells and provide evidence that bone defects in the Job Syndrome are likely caused by Wnt/β-catenin signaling reduction due to reduced STAT3 activities in bone development. Enhancing Wnt/β-catenin signaling could be a therapeutic approach to reduce bone symptoms of Job syndrome patients.

Entities:  

Keywords:  Job syndrome; Sost; Stat3; Wnt/beta-catenin signaling; bone development

Mesh:

Substances:

Year:  2021        PMID: 34172578      PMCID: PMC8256036          DOI: 10.1073/pnas.2020100118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  79 in total

Review 1.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Contrasting roles of leukemia inhibitory factor in murine bone development and remodeling involve region-specific changes in vascularization.

Authors:  Ingrid J Poulton; Narelle E McGregor; Sueli Pompolo; Emma C Walker; Natalie A Sims
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

3.  Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreER(T) to assay temporal activity windows along the proximodistal limb skeleton.

Authors:  Eiichiro Nakamura; Minh-Thanh Nguyen; Susan Mackem
Journal:  Dev Dyn       Date:  2006-09       Impact factor: 3.780

4.  Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes.

Authors:  Peter Dy; Weihuan Wang; Pallavi Bhattaram; Qiuqing Wang; Lai Wang; R Tracy Ballock; Véronique Lefebvre
Journal:  Dev Cell       Date:  2012-03-13       Impact factor: 12.270

5.  TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes.

Authors:  Nikolaos Doumpas; Franziska Lampart; Mark D Robinson; Antonio Lentini; Colm E Nestor; Claudio Cantù; Konrad Basler
Journal:  EMBO J       Date:  2018-11-13       Impact factor: 11.598

6.  Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.

Authors:  Y Z Wang; W Wharton; R Garcia; A Kraker; R Jove; W J Pledger
Journal:  Oncogene       Date:  2000-04-20       Impact factor: 9.867

7.  Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.

Authors:  Joshua D Milner; Tiphanie P Vogel; Lisa Forbes; Chi A Ma; Asbjørg Stray-Pedersen; Julie E Niemela; Jonathan J Lyons; Karin R Engelhardt; Yu Zhang; Nermina Topcagic; Elisha D O Roberson; Helen Matthews; James W Verbsky; Trivikram Dasu; Alexander Vargas-Hernandez; Nidhy Varghese; Kenneth L McClain; Lina B Karam; Karen Nahmod; George Makedonas; Emily M Mace; Hanne S Sorte; Gøri Perminow; V Koneti Rao; Michael P O'Connell; Susan Price; Helen C Su; Morgan Butrick; Joshua McElwee; Jason D Hughes; Joseph Willet; David Swan; Yaobo Xu; Mauro Santibanez-Koref; Voytek Slowik; Darrell L Dinwiddie; Christina E Ciaccio; Carol J Saunders; Seth Septer; Stephen F Kingsmore; Andrew J White; Andrew J Cant; Sophie Hambleton; Megan A Cooper
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

8.  Osteogenesis imperfecta tarda in a child with hyper-IgE syndrome.

Authors:  E P Brestel; W G Klingberg; R W Veltri; J S Dorn
Journal:  Am J Dis Child       Date:  1982-09

9.  Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer.

Authors:  Malcolm Logan; James F Martin; Andras Nagy; Corrinne Lobe; Eric N Olson; Clifford J Tabin
Journal:  Genesis       Date:  2002-06       Impact factor: 2.487

10.  High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.

Authors:  Paul J Niziolek; Bryan T MacDonald; Rajendra Kedlaya; Minjie Zhang; Teresita Bellido; Xi He; Matthew L Warman; Alexander G Robling
Journal:  J Bone Miner Res       Date:  2015-10       Impact factor: 6.741

View more
  2 in total

1.  Self-amplifying loop of NF-κB and periostin initiated by PIEZO1 accelerates mechano-induced senescence of nucleus pulposus cells and intervertebral disc degeneration.

Authors:  Jinna Wu; Yuyu Chen; Zhiheng Liao; Hengyu Liu; Shun Zhang; Dongmei Zhong; Xianjian Qiu; Taiqiu Chen; Deying Su; Xiaona Ke; Yong Wan; Taifeng Zhou; Peiqiang Su
Journal:  Mol Ther       Date:  2022-05-26       Impact factor: 12.910

Review 2.  Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases.

Authors:  Jiadong Li; Zhifeng Yin; Biaotong Huang; Ke Xu; Jiacan Su
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.